BioPharma Resources

Drug Trial Radar · NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,438 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,438

Planned (sponsor's estimate)

Start

Aug 12, 2025

Primary completion

Mar 2028

Study completion Mar 2030

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

Conditions

  • Advanced Solid Tumor

Interventions

  • BNT326Drug

    Intravenous (IV) infusion

  • PumitamigDrug

    IV infusion

  • ItraconazoleDrug

    Oral administration

  • ParoxetineDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)Time frame: from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
  2. Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEsTime frame: from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)
  3. Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)Time frame: from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)
  4. Part 2 - Occurrence of dose limiting toxicities (DLTs)Time frame: from the time of initiation of the first dose of IMP up to 21 days
  5. Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 ADC and unconjugated payloadTime frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose
  6. Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 ADC and unconjugated payloadTime frame: from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose

Locations

79 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Not yet recruiting

  • University of California San Francisco

    San Francisco, California · Not yet recruiting

  • Hartford Healthcare

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Not yet recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigitte Harris Cancer Pavilion BHCP

    Detroit, Michigan · Recruiting

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Memorial Sloan Kettering Hospital

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Not yet recruiting

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics (START), LLC

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • The Board of Regents of the University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Recruiting

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia · Recruiting

  • Tasman Oncology Research Ltd

    Southport, Queensland, Australia · Recruiting

  • Cancer Research SA

    Adelaide, South Australia, Australia · Recruiting

  • Peninsula and South Eastern Haematology & Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • One Clinical Research Pty Ltd

    Nedlands, Western Australia, Australia · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Centre hospitalier universitaire de Liège

    Liège, Belgium · Recruiting

  • Ziekenhuis Aan de Stroom ZAS vzw

    Wilrijk, Belgium · Recruiting

  • Affiliated Hospital of Hebei University

    Baoding, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, China · Recruiting

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, China · Recruiting

  • Charité - Campus Charité Mitte

    Berlin, Germany · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.